OPHLF News and Press, Ono Pharmaceutical Co Ltd From 07/30/21

Ono Pharmaceutical (OTC:OPHLF): Q1 GAAP EPS of ¥48.22. Revenue of ¥87.36B (+16.6% Y/Y). Press Release For further details see: Ono Pharmaceutical reports Q1 results

Bristol Myers Squibb (NYSE: BMY) and Exelixis, Inc. (EXEL) disclosed new data for Opdivo/ Cabometyx combo in a pivotal Phase 3 trial for the first-line treatment of advanced renal cell carcinoma.The trial sponsored by Bristol Myers Squibb and Ono Pharmaceutical (OPHLF) and co-funded by Exelix...

New York City, NY:March 26, 2020 – Published via (Wired Release) – Recent Research and Future Market Potential of Alzheimer’s Drugs Market in Global Industry: 2020 Research and New Innovations in Chemicals and Materials Sector. The prime objective of the report is to offer...

Citing encouraging results from a Phase 1 study in Japan, Bayer ( OTCPK:BAYRY ), Bristol-Myers Squibb (NYSE: BMY ) and Ono Pharmaceutical Co. ( OTC:OPHLF ) will collaborate on a clinical trial evaluating the combination Stivarga (regorafenib) and Opdivo (nivolumab) in patients with microsa...

Since I have last written on Array ( ARRY ), the stock price has risen from $13.43 to $20.96 at the close of the market on 2/5/19. While this is a nice gain, the fundamentals of the company have also improved, suggesting there is much more room for this Mid-Cap biotech to run. While my last ...